Abcam, ab52587, Anti-PD1 antibody [NAT105]

Size: 100µg / 1mg
Anti-PD1 antibody [NAT105] (ab52587) is a mouse monoclonal antibody detecting PD1 in Western Blot, Flow Cytometry, IHC-P, IHC-Fr, ICC/IF . Suitable for Human . - Over 280 publications - Trusted since 2007
Key facts
Host species:Mouse,
Clonality:Monoclonal,
Clone number:NAT105,
Isotype:IgG1,
Light chain type:kappa,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, WB, ICC/IF, Flow Cyt, IHC-FrSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Anti-PD1 antibody [NAT105] (ab52587) is a mouse recombinant monoclonal antibody and is validated for use in Flow Cyt, ICC/IF, IHC-Fr, IHC-P and WB.
Anti-PD1 antibody [NAT105] (ab52587) was first used in a scientific publication in 2007 and has been cited over 282 times in peer reviewed journals. It's performance in IHC in human samples is trusted by the scientific community.
Abcam's high quality manufacturing and validation processes ensure Anti-PD1 antibody [NAT105] (ab52587) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility.
Anti-PD1 antibody [NAT105] (ab52587) has 8 independent reviews from customers.
Anti-PD1 antibody [NAT105] (ab52587) specifically detects PD1 (UniProt ID: Q15116; Molecular weight: 29kDa) and is sold in a convenient trial size to enable initial testing (20 µg) and larger sizes for subsequent scaling up experiments (100 ug and 1 mg).
Conjugation-ready, carrier free format available for antibody clone NAT105 -
ab201811
Antibody clone NAT105 is also available pre-conjugated to a variety of labels for your convenience - Alexa Fluor
488, Alexa Fluor
647, PE, Alexa Fluor
647, Alexa Fluor
ab220300
ab220301
ab220302
ab279695
ab280864
PD-1 is an immune checkpoint receptor that, when engaged by its ligands PD-L1 or PD-L2, inhibits T-cell activity, allowing tumors to evade immune detection. Blocking the PD-1 pathway with immune checkpoint inhibitors reactivates T-cells, enhancing the immune system's ability to target and destroy cancer cells.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Programmed cell death protein 1 commonly known as PD-1 or PDCD1 is an immune checkpoint receptor with a molecular mass of approximately 55 kDa. This protein is primarily expressed on the surface of activated T cells B cells and myeloid cells within the immune system. PD-1 plays a mechanical role in modulating immune responses by binding to its ligands PD-L1 and PD-L2 which are expressed on other immune cells and in various other tissues. The engagement of PD-1 with its ligands transmits an inhibitory signal that reduces the proliferation and activity of T cells.
Biological function summary
PD-1 serves as a critical immune checkpoint that helps maintain self-tolerance and prevent autoimmunity. PD-1 does not function as part of a multi-protein complex but independently regulates the immune response. By delivering inhibitory signals upon ligand binding PD-1 limits the overactivation of the immune system reducing the likelihood of tissue damage during inflammatory responses. The modulation of T cell activity by PD-1 contributes to a balanced immune system ensuring that the body targets pathogens effectively without harming itself.
Pathways
PD-1 interacts with key immune-regulatory pathways including the PI3K-Akt and Ras-MAPK pathways. These pathways are important for cell survival growth and metabolism. The interaction of PD-1 with the PI3K-Akt pathway involves proteins such as SHP-2 which dephosphorylates signaling intermediates leading to reduced T cell receptor signaling. PD-1's role in these pathways demonstrates its influence on immune cell function particularly in regulating the intensity and duration of immune responses.
The PD-1 pathway plays an important role in cancer and autoimmune diseases. Tumors often exploit the PD-1 pathway to evade immune surveillance leading to cancer progression. In such cases blocking PD-1 with inhibitors like anti-PD-1 antibodies (e.g. EH12.2H7 and chimeric antibodies) can re-activate T cells against cancer cells. Conversely in autoimmune diseases heightened PD-1 expression or activity could help in moderating aberrant immune responses where the immune system attacks the body's own tissues. The PD-1 pathway interacting with proteins such as CTLA-4 in cancer and autoimmune contexts represents a target for therapeutics aiming to modulate the immune system to improve disease outcomes.